Lumbar spine bone mineral density: molecular mechanisms & dependencies

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

Human evidence only

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

Lumbar-spine BMD was preserved relative to placebo: change difference 0.050 g/cm2, 95% CI 0.015–0.085; other measured sites had no significant effect.
Menaquinone-7 / MK-7 → Lumbar spine bone mineral density source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/k2-research/36460034.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7a8ad2542116a1ddc804eead1694c7057dfaff243eacb993c6c39745e73264a0", "start_char": 0, "end_char": 1754, "text_sha256": "7a8ad2542116a1ddc804eead1694c7057dfaff243eacb993c6c39745e73264a0"}
experimental_model
Two-year randomized double-blind RenaKvit trial
exposure
MK-7 360 micrograms/day versus placebo
limitations
Kidney-disease context and substantial attrition; site-specific findings cannot be condensed into universal bone benefit or harm.
nutrient_topic
Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin K2 / menaquinone family
organism
123 chronic-dialysis patients randomized
plain_language
A different skeletal site in the same trial had a favorable result.
primary_references
[k2-p36460034] Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial. (2023). https://pubmed.ncbi.nlm.nih.gov/36460034/ DOI: 10.1093/ndt/gfac315
tissue_or_cell_type
Site-specific BMD
Vitamin K2: menaquinone forms, carboxylation, recycling and nutrient interactions (2026-09-17) · lines 1137–1148
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two-year randomized double-blind RenaKvit trial · source_derived_draft · unverified_draft
### k2-dialysis-spine Lumbar-spine BMD was preserved relative to placebo: change difference 0.050 g/cm2, 95% CI 0.015–0.085; other measured sites had no significant effect. Condition category: normal nutrient_topic: Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. plain_language: A different skeletal site in the same trial had a favorable result. organism: 123 chronic-dialysis patients randomized tissue_or_cell_type: Site-specific BMD experimental_model: Two-year randomized double-blind RenaKvit trial limitations: Kidney-disease context and substantial attrition; site-specific findings cannot be condensed into universal bone benefit or harm. exposure: MK-7 360 micrograms/day versus placebo evidence_span: {"source_cache": "artifacts/k2-research/36460034.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "7a8ad2542116a1ddc804eead1694c7057dfaff243eacb993c6c39745e73264a0", "start_char": 0, "end_char": 1754, "text_sha256": "7a8ad2542116a1ddc804eead1694c7057dfaff243eacb993c6c39745e73264a0"} [k2-p36460034] Vitamin K supplementation and bone mineral density in dialysis: results of the double-blind, randomized, placebo-controlled RenaKvit trial. (2023). https://pubmed.ncbi.nlm.nih.gov/36460034/ DOI: 10.1093/ndt/gfac315
Complete structured claim and evidence
MK-7 reduced age-related loss of lumbar-spine and femoral-neck BMD/BMC, but not total-hip BMD, over three years.
Menaquinone-7 / MK-7 → Lumbar spine bone mineral density source_derived_draftungraded
Experimental context and source evidence
evidence_span
{"source_cache": "artifacts/k2-research/23525894.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a3ce7b3935f14513cb967410370b1bca786c7548989964d658077108e362f4dc", "start_char": 0, "end_char": 2060, "text_sha256": "a3ce7b3935f14513cb967410370b1bca786c7548989964d658077108e362f4dc"}
experimental_model
Three-year double-blind placebo-controlled trial
exposure
MK-7 180 micrograms/day
limitations
Site-specific surrogate outcomes; not proof of fracture prevention in every population. The arterial-stiffness publication describes the same cohort.
nutrient_topic
Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin K2 / menaquinone family
organism
244 healthy postmenopausal women
plain_language
The result differed by skeletal site.
primary_references
[k2-p23525894] Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. (2013). https://pubmed.ncbi.nlm.nih.gov/23525894/ DOI: 10.1007/s00198-013-2325-6
tissue_or_cell_type
DXA and osteocalcin markers
Vitamin K2: menaquinone forms, carboxylation, recycling and nutrient interactions (2026-09-17) · lines 1072–1083
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Three-year double-blind placebo-controlled trial · source_derived_draft · unverified_draft
### k2-mk7-bone-positive MK-7 reduced age-related loss of lumbar-spine and femoral-neck BMD/BMC, but not total-hip BMD, over three years. Condition category: normal nutrient_topic: Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect. plain_language: The result differed by skeletal site. organism: 244 healthy postmenopausal women tissue_or_cell_type: DXA and osteocalcin markers experimental_model: Three-year double-blind placebo-controlled trial limitations: Site-specific surrogate outcomes; not proof of fracture prevention in every population. The arterial-stiffness publication describes the same cohort. exposure: MK-7 180 micrograms/day evidence_span: {"source_cache": "artifacts/k2-research/23525894.abstract.txt", "locator": "Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "a3ce7b3935f14513cb967410370b1bca786c7548989964d658077108e362f4dc", "start_char": 0, "end_char": 2060, "text_sha256": "a3ce7b3935f14513cb967410370b1bca786c7548989964d658077108e362f4dc"} [k2-p23525894] Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women. (2013). https://pubmed.ncbi.nlm.nih.gov/23525894/ DOI: 10.1007/s00198-013-2325-6
Complete structured claim and evidence

The events it takes part in

A mechanism often involves more than two components. These are the full events, with every participant and its role.

Situations it appears in

Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

Open hypotheses

Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.

This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

Lumbar spine bone mineral density